Goodwin advised ReViral on the deal. Clifford Chance advised Pfizer. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to...
You must be a Standard 1 Year member to access this content.
Goodwin advised SV Health, Jeito and Samsara BioCapital on the deal. SV Health, Jeito and Samsara BioCapital led a $65 million Series A Financing of EyeBio. EyeBio...
You must be a Standard 1 Year member to access this content.
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
You must be a Standard 1 Year member to access this content.
Goodwin advised BIVF, Novo and Evotec on the deal. Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bio Products Laboratory and Tiancheng International Investment Limited on the deal. The shareholders of Kedrion was advised by Carnelutti and Pedersoli Studio Legale,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Omega Funds on the deal. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
